NeoPharm CO., LTD. (KOSDAQ:092730)

NeoPharm CO., LTD. Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	18,234	11,881	10,883	7,049	11,189
Short-Term Investments	108,290	98,026	102,000	98,000	84,000
Trading Asset Securities	-	2,083	602.5	-	992.06
Cash & Short-Term Investments	126,524	111,990	113,485	105,049	96,181
Cash Growth	12.98%	-1.32%	8.03%	9.22%	12.47%
Accounts Receivable	10,846	8,555	6,543	7,513	8,322
Other Receivables	1,905	1,809	1,103	514.09	527.14
Receivables	12,762	10,383	7,665	8,045	8,863
Inventory	12,676	10,195	8,749	7,973	8,090
Prepaid Expenses	152.09	461.05	61.34	66.55	259.57
Other Current Assets	935.9	1,474	1,309	349.62	158.57
Total Current Assets	153,050	134,502	131,270	121,484	113,551
Property, Plant & Equipment	29,764	29,244	9,341	9,743	10,121
Long-Term Investments	1,310	4,684	6,369	3,559	647.85
Other Intangible Assets	1,951	2,237	1,786	2,055	2,380
Long-Term Deferred Tax Assets	19.41	436.34	135.32	171.21	375.56
Other Long-Term Assets	6,211	6,220	6,328	6,280	5,786
Total Assets	192,440	177,459	155,347	143,408	132,978
Accounts Payable	5,030	6,435	3,703	4,347	4,194
Accrued Expenses	-	-	-	-	1.06
Current Portion of Long-Term Debt	-	17.68	18.59	19.27	4,020
Current Portion of Leases	500.41	617.57	393.58	437.71	270.65
Current Income Taxes Payable	3,461	3,876	3,778	3,145	2,291
Current Unearned Revenue	27.43	2.24	-	-	-
Other Current Liabilities	6,109	5,997	5,244	4,992	4,100
Total Current Liabilities	15,128	16,945	13,137	12,941	14,877
Long-Term Leases	128.99	430.05	-	101.79	19.37
Other Long-Term Liabilities	298.54	57.73	-	0	0
Total Liabilities	15,555	17,433	13,137	13,103	15,260
Common Stock	8,014	4,104	4,104	4,104	4,104
Additional Paid-In Capital	41,223	45,170	45,170	45,170	45,133
Retained Earnings	130,569	113,603	96,106	83,848	71,100
Treasury Stock	-2,679	-2,679	-2,679	-2,679	-2,679
Comprehensive Income & Other	-242.89	-171.99	-490.33	-138.2	59.47
Shareholders' Equity	176,885	160,026	142,211	130,305	117,718
Total Liabilities & Equity	192,440	177,459	155,347	143,408	132,978
Total Debt	629.4	1,065	412.16	558.77	4,310
Net Cash (Debt)	125,895	110,925	113,073	104,490	91,871
Net Cash Growth	13.50%	-1.90%	8.21%	13.74%	13.65%
Net Cash Per Share	8048.91	7091.80	7229.16	6680.42	5818.13
Filing Date Shares Outstanding	15.64	15.64	15.64	15.64	15.64
Total Common Shares Outstanding	15.64	15.64	15.64	15.64	15.64
Working Capital	137,922	117,558	118,133	108,543	98,675
Book Value Per Share	11308.86	10231.02	9092.03	8330.85	7526.09
Tangible Book Value	174,934	157,789	140,424	128,250	115,337
Tangible Book Value Per Share	11184.13	10088.01	8977.82	8199.46	7373.90
Land	8,554	8,554	1,202	1,223	1,286
Buildings	20,888	18,345	9,791	9,881	10,248
Machinery	9,508	8,214	6,086	6,043	5,798
Construction In Progress	273.19	1,686	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.